Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thierry Facon

Showing results (211-220 of 257) with videos related to

Pageof 26
Sort By:
Blood|August 19, 2011
Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myelomaPhilippe Moreau, Herve Avet-Loiseau, Thierry Facon, et al.
Haematologica|April 15, 2014
Age is a prognostic factor even among patients with multiple myeloma younger than 66 years treated with high-dose melphalan: the IFM experience on 2316 patientsMarie-Lorraine Chretien, Benjamin Hebraud, Valérie Cances-Lauwers, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 29, 2020
<i>BRAF</i> and <i>DIS3</i> Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple MyelomaEileen M Boyle, Cody Ashby, Ruslana G Tytarenko, et al.
Blood Advances|June 3, 2026
Daratumumab in Transplant-Ineligible or -Deferred Newly Diagnosed Multiple Myeloma: Minimal Residual Disease in CEPHEUSSonja Zweegman, Thierry Facon, Vania Hungria, et al.
The New England Journal of Medicine|May 30, 2019
Daratumumab plus Lenalidomide and Dexamethasone for Untreated MyelomaThierry Facon, Shaji Kumar, Torben Plesner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 8, 2017
Prospective Evaluation of Magnetic Resonance Imaging and [<sup>18</sup>F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM StudyPhilippe Moreau, Michel Attal, Denis Caillot, et al.
Annals of Hematology|January 14, 2018
Salvage therapy post pomalidomide-based regimen in relapsed/refractory myelomaGuillemette Fouquet, Lionel Karlin, Margaret Macro, et al.
Blood|October 31, 2015
Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter?Marie-Lorraine Chretien, Jill Corre, Valerie Lauwers-Cances, et al.
Haematologica|September 29, 2022
Heterogeneity in long-term outcomes for patients with Revised International Staging System stage II, newly diagnosed multiple myelomaAnais Schavgoulidze, Valerie Lauwers-Cances, Aurore Perrot, et al.
Leukemia|August 21, 2020
Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma NetworkHeinz Ludwig, Mario Boccadoro, Philippe Moreau, et al.
Pageof 26

Showing results (211-220 of 257) with videos related to

Sort By:
Pageof 26
Blood|August 19, 2011
Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myelomaPhilippe Moreau, Herve Avet-Loiseau, Thierry Facon, et al.
Haematologica|April 15, 2014
Age is a prognostic factor even among patients with multiple myeloma younger than 66 years treated with high-dose melphalan: the IFM experience on 2316 patientsMarie-Lorraine Chretien, Benjamin Hebraud, Valérie Cances-Lauwers, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 29, 2020
<i>BRAF</i> and <i>DIS3</i> Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple MyelomaEileen M Boyle, Cody Ashby, Ruslana G Tytarenko, et al.
Blood Advances|June 3, 2026
Daratumumab in Transplant-Ineligible or -Deferred Newly Diagnosed Multiple Myeloma: Minimal Residual Disease in CEPHEUSSonja Zweegman, Thierry Facon, Vania Hungria, et al.
The New England Journal of Medicine|May 30, 2019
Daratumumab plus Lenalidomide and Dexamethasone for Untreated MyelomaThierry Facon, Shaji Kumar, Torben Plesner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 8, 2017
Prospective Evaluation of Magnetic Resonance Imaging and [<sup>18</sup>F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM StudyPhilippe Moreau, Michel Attal, Denis Caillot, et al.
Annals of Hematology|January 14, 2018
Salvage therapy post pomalidomide-based regimen in relapsed/refractory myelomaGuillemette Fouquet, Lionel Karlin, Margaret Macro, et al.
Blood|October 31, 2015
Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter?Marie-Lorraine Chretien, Jill Corre, Valerie Lauwers-Cances, et al.
Haematologica|September 29, 2022
Heterogeneity in long-term outcomes for patients with Revised International Staging System stage II, newly diagnosed multiple myelomaAnais Schavgoulidze, Valerie Lauwers-Cances, Aurore Perrot, et al.
Leukemia|August 21, 2020
Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma NetworkHeinz Ludwig, Mario Boccadoro, Philippe Moreau, et al.
Pageof 26